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Abstract
The Hippo pathway restricts the activity of transcriptional coactivators TAZ (WWTR1) and YAP. TAZ and YAP are reported to
be overexpressed in various cancers, however, their prognostic significance in colorectal cancers remains unstudied. The
expression levels of TAZ and YAP, and their downstream transcriptional targets, AXL and CTGF, were extracted from two
independent colon cancer patient datasets available in the Gene Expression Omnibus database, totaling 522 patients. We
found that mRNA expressions of both TAZ and YAP were positively correlated with those of AXL and CTGF (p,0.05). High
level mRNA expression of TAZ, AXL or CTGF significantly correlated with shorter survival. Importantly, patients co-
overexpressing all 3 genes had a significantly shorter survival time, and combinatorial expression of these 3 genes was an
independent predictor for survival. The downstream target genes for TAZ-AXL-CTGF overexpression were identified by Java
application MyStats. Interestingly, genes that are associated with colon cancer progression (ANTXR1, EFEMP2, SULF1, TAGLN,
VCAN, ZEB1 and ZEB2) were upregulated in patients co-overexpressing TAZ-AXL-CTGF. This TAZ-AXL-CTGF gene expression
signature (GES) was then applied to Connectivity Map to identify small molecules that could potentially be utilized to
reverse this GES. Of the top 20 small molecules identified by connectivity map, amiloride (a potassium sparing diuretic,) and
tretinoin (all-trans retinoic acid) have shown therapeutic promise in inhibition of colon cancer cell growth. Using MyStats,
we found that low level expression of either ANO1 or SQLE were associated with a better prognosis in patients who co-
overexpressed TAZ-AXL-CTGF, and that ANO1 was an independent predictor of survival together with TAZ-AXL-CTGF.
Finally, we confirmed that TAZ regulates Axl, and plays an important role in clonogenicity and non-adherent growth in vitro
and tumor formation in vivo. These data suggest that TAZ could be a therapeutic target for the treatment of colon cancer.
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Introduction
The Hippo pathway plays an important role in cell prolifera-
tion, organ size control, and cancer development and progression
[1,2,3,4]. YAP and TAZ are both transcriptional co-activators that
are inhibited by the Hippo pathway [1,2,3,4]. Aberrant inactiva-
tion of the Hippo pathway and/or overexpression of TAZ and
YAP results in transcriptional activation of their downstream
targets [1,2,3,4].
YAP overexpression induces cell proliferation and epithelial
mesenchymal transition (EMT), and inhibits apoptosis and contact
inhibition [5,6,7]. Transcriptional activation of epidermal growth
factor receptor ligand amphiregulin may account for YAP-
mediated induction of cell proliferation, especially under serum-
depletion [7], while YAP also cooperates with Myc to promote cell
proliferation [8]. Recently, YAP has been shown to play a critical
role in stem cell biology. It is induced during pluripotent stem cell
reprogramming, whilst silencing of YAP reduces the pluripotency
of embryonic stem cells [9]. YAP promotes ovarian cancer
progression, and high levels of nuclear expression are inversely
associated with patient survival [10]. In particular, YAP is
associated with clear cell ovarian tumors, an ovarian malignancy
subtype with poor prognosis [11]. YAP has also been shown to
play an oncogenic role in esophageal squamous cell carcinoma
[12]. In liver cancer, microRNA-mediated inhibition of YAP
inhibits tumor characteristics including cell proliferation and
invasion [13]. Conversely, there are reports showing an opposite,
tumor suppressive, role of YAP in promoting p73-mediated
apoptosis [14,15]. In breast and head and neck cancers, YAP has
been shown to act as a tumor suppressor in certain circumstances
[14,16].
TAZ is structurally homologous to YAP, is likewise inhibited by
the Hippo pathway, and also promotes EMT-mediated cancer
progression [17,18,19]. TAZ regulates mesenchymal stem cell
differentiation by modulating Runx2- and PPARgamma-depen-
dent gene expression [20], as well as stem cell self-renewal through
controlling localization of Smad [21]. TAZ plays an important
role in the progression of breast [22,23] and non-small cell lung
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cancer [24,25]. Importantly, TAZ confers cancer stem cell-related
traits on breast cancer cells, further highlighting its importance in
tumor initiation and progression [26]. TAZ is also overexpressed
in papillary thyroid carcinoma [27].
TAZ and YAP have been shown to interact with several
transcriptional factors [2,3,4], with the TEAD family of transcrip-
tional factors (TEAD1-4) being the most relevant in cell
proliferation and cancer progression [19,28,29]. The X-ray crystal
structures of YAP-TEAD complexes have been resolved and the
proposed interaction is supported by and consistent with
functional analysis [30,31,32], showing that YAP-TEAD com-
plexes activates gene transcription.
YAP expression was observed in colon adenocarcinoma
[33,34,35]. It is overexpressed in human colon cancer specimens
and overexpression of YAP promotes cell proliferation and
survival in colon cancer cells [36]. Recent findings show that
knockdown of TAZ results in a decrease in cell proliferation in
culture and tumor growth in vivo [26].
Despite evidence suggesting the potential implication of YAP
and TAZ in colon cancer progression, their prognostic significance
in colorectal cancer is unknown. In this study, we analyzed the
mRNA expression of YAP and TAZ, and two of its downstream
target genes, AXL and CTGF, in two independent colon cancer
patient cohorts comprising 522 patients. We found that TAZ, but
not YAP, is a prognostic marker in colon cancer progression.
Furthermore, TAZ-AXL-CTGF co-overexpression, which defines
both the expression of TAZ and its transcriptional activity on
target gene expression, is a novel prognostic indicator, that is
independent of tumor grade and stage, for colon cancer patients.
The role of TAZ in colon cancer cell proliferation and oncogenesis
was validated by functional study.
Materials and Methods
Extraction of clinical and microarray gene expression
data from colon cancer patient datasets
Two colon cancer patient datasets, GSE14333 [37] and
GSE17538 [38], available in the Gene Expression Omnibus
(GEO) Database (http://www.ncbi.nlm.nih.gov/gds) were included
in this study. The GEO website has standardized URLs for its
individual datasets, e.g. the overall summary information about the
microarray dataset GSE14333 can be accessed at http://www.ncbi.
nlm.gov/geo/query/acc.cgi?acc=GSE14333. For each GEO data
series, links are provided at the bottom of the page to the Series
Matrix File(s), which contain the expression values for each gene
(probeset) and each microarray. The URLs to the Series Matrix
File(s) are also standardized. For GSE14333, the URLwas ftp://ftp.
ncbi.nlm.nih.gov/pub/geo/DATA/SeriesMatrix/GSE14333. The
files in gzip format were then unzipped to the tab-delimited text
format, which contain detailed information for statistical analysis.
The GSE14333 and GSE17538 datasets are the two largest colon
cancer patient datasets on the database, and comprise 522 patients,
458 of whose survival data is available in the database.
The GSE17538 data series consists of four SubSeries: GSE17536,
GSE17537, GSE19072 and GSE19073. GSE19072 and
GSE19073 were excluded from this study as they lack clinical data.
Microarray gene expression data were retrieved from the data
matrices deposited to the GEO database by the original authors.
The gene expression levels in GSE14333 and GSE17538 are
represented by base-2 logarithm of the MAS5 value and the RMA
values, respectively, as adopted by the original authors. R scripting
was used to extract the expression values of a small number of genes
(probesets) of interest and the clinical data from the data matrixes
downloaded from GEO.
Demographic and clinical data of the two patient cohorts
Both age and gender of the patients were available demographic
data in the two datasets analyzed in the present study. Patients had
a median age of 67 years (Range: 26–92 year-old) and 65.5 years
(Range: 23–94 year-old) in GSE14333 and GSE17538, respec-
tively. There were 43% and 46% female, respectively, in cohort
GSE14333 and GSE17538. The GSE14333 cohort consists of 290
patients, for whom 226 survival data were available. Fifteen, 32,
31 and 21% of patients had stage A, B, C and D tumors,
respectively. The survival data were not available for all the
patients of stage D. Survival data were available for all 232
patients in the GSE17538 cohort. Twelve, 31, 33 and 24%
patients had tumors of AJCC stage I, II, III and IV, respectively,
and 8, 78 and 14% of patients had Grade A, B and C tumors
respectively.
Correlations of gene expression levels and clinical data
All statistical analyses were performed using SPSS19.0. The
associations between expression levels of genes were analyzed by
Spearman’s rank test. Expression levels were further divided into
high and low levels using median expression level as the cut-off
point for Kaplan-Meier survival analysis. Results were compared
by log-rank test. Univeriate Cox regression analysis was used to
correlate the gene expression levels and patient survival and
multivariate Cox regression analysis was used to identify
independent predictors for patient survival using a backward
stepwise approach with an entry limit of p,0.1 and a removal
limit of p.0.05. Patients were divided further into 4 groups based
on the expression levels of TAZ, AXL and CTGF; the TAZ-AXL-
CTGF-low group consisted of patients who expressed all these 3
genes at low levels; the TAZ-AXL-CTGF-intermediate-low group
consisted of patients who expressed one of these three genes at a
high level; the TAZ-AXL-CTGF-intermediate-high group con-
sisted of patients who expressed two of these three genes at high
levels; the TAZ-AXL-CTGF-high group consisted of patients who
expressed all three genes at high levels. The survival time of
patients stratified by this grouping method were analyzed by
Kaplan-Meier analysis and Cox regression as described above.
Identification of TAZ-AXL-CTGF co-expressing genes
Patients were stratified into four groups based on the expression
levels of TAZ, AXL and CTGF as described above. The gene
expression patterns of patients in TAZ-AXL-CTGF low subgroup
and those in the TAZ-AXL-CTGF high subgroup (whose survival
was significantly poorer) were compared. Probesets that were
differentially expressed between these two subgroups were
identified by 2-sample Welch’s T-test. This test was used to avoid
the type I error due to unequal variances of the values of probesets
between subgroups. Briefly, a Welch’s t test was applied to each
probeset corresponding to a certain gene in the data matrix using
our own Java application MyStats. P values and the differential
expression in fold changes for all the probesets were generated as
tab-delimited worksheets of Excel for further analysis. The genes
were prioritized by ascending p-values. The top 100 probesets
were prioritized in both patient datasets, and the genes common to
both datasets were analyzed further.
Identification of potential inhibitory compounds
targeting TAZ-AXL-CTGF overexpressing colon cancer
(Connectivity Map)
Gene expression connectivity mapping was performed using
Statistically Significant Connection’s Map (sscMap) to identify
candidate small molecule compounds that may inhibit the
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expression of genes that are co-regulated in TAZ-AXL-CTGF co-
expressing aggressive colon cancer [39,40,41]. Of the probesets
identified to be co-expressed with TAZ-AXL-CTGF, 33 were
present on the Affymetrix HG-U133A microarray platform, which
was used to generate the microarray database for the Connectivity
Map [39]. The compiled gene signature was then fed to the Java
application sscMap [41] as a query signature, and its association
with the 6000 gene expression profiles generated by treating
cancer cells with over 1000 small molecules were compared. The
gene signature perturbation procedure, which increases the
specificity of the output results, was applied as previously described
[42]. All the small molecular compounds, that were negatively
associated with the TAZ-AXL-CTGF-GES, were sorted and
ranked by their p-value, perturbation stability and standardized
connection score. The p-value that was considered significant was
set at a stringent threshold (p= 1/1309), ensuring that the results
generated by sccMap yield only maximally one expected false
positive small molecule over the 1309 small molecules tested in the
sccMap [42]. The top 20 small molecules were then entered into
the Pubmed (www.pubmed.com) search engine together with
colon cancer to identify research articles that have described their
effects of the particular molecules on treatment of colon cancer.
Identification of therapeutic targets for colon cancer
patients overexpressing TAZ-AXL-CTGF
Patients who co-overexpressed TAZ-AXL-CTGF were strati-
fied into two groups based on their survival statuses. Differential
expressions of different probesets between patients in the TAZ-
AXL-CTGF-alive subgroup and those in the TAZ-AXL-CTGF-
deceased subgroup were identified as described above.
Cell culture and retroviral transduction
HCT116 and SW620 cells were obtained from American Type
Culture Collection and maintained in F12K/DME medium
supplemented with 10% Fetal Bovine Serum (FBS), 10 ug/ml
Penicillin/Streptomycin (P/S) (Life technologies, Carlsbad, CA).
The amphotropic Phoenix packaging cell line was obtained from
the Nolan Laboratory (Stanford University) and maintained in
DMEMmedium supplemented with 10% FBS and 10 ug/ml P/S.
Retroviral infection was performed as previously described [18].
The short hairpin (shRNA) against human TAZ construct (59-
AGGTACTTCCTCAATCACA-39) carried by the pSuperRetro-
puro vector (shTAZ) was used for TAZ knockdown (Oligoengine,
Seattle, WA) while the scramble shRNA construct (59-
CCTAAGGTTAAGTCGCCCTCG-39; shScr) was used for
control. Stable cell lines were established by selecting the traduced
cells in 2 ug/ml puromycin (Sigma Aldrich, St. Louis, MO).
Western blot analysis
Immunoblotting was performed as previously described [18]
using SuperSignal West Pico (Thermo Scientific, Rockford, IL).
The commercial TAZ antibody was obtained from Imgenex (San
Diego, CA).
Anchorage-independent soft agar and clonogenic assays
For the soft agar assay, 5000 cells resuspended in 0.35% (w/v)
agarose in culture medium were overlaid on a solidified 0.5% (w/
v) agarose in culture medium. The upper layer was allowed to
solidify. Medium with puromycin was added the following day and
cells were then incubated at 37u-C with 5% CO2. Fresh medium
with puromycin was supplemented and the colonies formed were
stained with 1 mg/ml Thiazolyl Blue Tetrazolium Bromide
(Sigma Aldrich) for 4 hours in the incubator at 37uC with 5%
CO2. The excess dye was removed by destaining multiple times
with water and the number of colonies was determined.
For clonogenic assay, 500 cells were seeded per well in triplicate
in 6-well plate. The culture medium was refreshed every week and
the cells were fixed with 4% paraformaldehyde in PBS after 2
weeks incubation at 37uC with 5% CO2. The fixed cells were
stained with 0.5% crystal violet (Sigma Aldrich) in 20% ethanol
overnight. The cells were rinsed with water, dried and colony
number was analyzed.
Tumorigenesis in nude mice
Hundred ul of a cell suspension of 1.56107/ml were inoculated
subcutaneously in the left and right hind flanks of four-to-six week-
old female nude mice. Tumor development was monitored sfter 2
weeks. Mice were then euthanized and the tumors were removed
for analysis.
Results
TAZ and YAP mRNA expressions positively correlate with
mRNA expression of their downstream target genes, AXL
and CTGF
Previously, we and others have shown that AXL and CTGF are
two important downstream target genes of TAZ and YAP
[23,43,44]. In the present study, we investigated whether the
mRNA expression levels of the two transcriptional co-activators in
the Hippo pathway, TAZ and YAP, correlate with the mRNA
expression of AXL and CTGF. In the 290 colon cancer patients
from the GSE14333 dataset, TAZ expression was significantly
correlated with both AXL (Spearman’s rank test, r=0.547,
p,0.001; Figure 1A) and CTGF (r=0.543, p,0.001; Figure 1B)
expressions. YAP mRNA expression was also positively correlated
with AXL (r=0.154, p=0.009; Figure 1C) and CTGF (r=0.141,
p=0.016; Figure 1D) mRNA expression in the same dataset, but
to a lesser extent. In 232 colon cancer patients from GSE17538,
TAZ mRNA expression was significantly positively correlated with
both AXL (r=0.752, p,0.001; Figure 1E) and CTGF (r=0.686,
p,0.001; Figure 1F) mRNA expressions, while YAP mRNA was
also significantly positively correlated with mRNA expression of
both genes, again to a lesser extent (AXL: r=0.343, p,0.001;
Figure 1G and CTGF: r=0.387, p,0.001; Figure 1H).
TAZ, but not YAP, mRNA expression is a predictor for
patient survival
In the 226 patients whose survival data were available from the
GSE14333 colon cancer patient cohort, a high level of TAZ
mRNA expression was significantly correlated with a shorter
survival (high level: mean survival = 72.3 months, 95% Confidence
Interval (CI) = 63–81 months; low level: mean survival = 129
months, 95% CI= 121–136 months, p,0.001; Figure 2A). By
Cox-regression analysis, TAZ mRNA expression was significantly
correlated with survival (Hazards Ratio (HR)= 2.251, 95%
CI= 1.626–3.116, p,0.001; Figure 2C) in the GSE14333 colon
cancer patient cohort. By multivariate analysis (Figure 2C), TAZ
mRNA expression (HR=2.062, 95% CI= 1.472–3.116, p,0.001)
and tumor staging (p,0.001) are both independent predictors of
survival in the same cohort. Similarly, a high level of TAZ mRNA
expression was significantly correlated with shorter patient survival
in the GSE17538 colon cancer patient cohort (high level: mean
survival = 84 months, 95% CI= 72–96 months; low level: mean
survival = 109 months, 95% CI=97–120 months, p=0.011;
Figure 2B). By Cox-regression, TAZ mRNA expression is a
predictor of survival in this cohort (HR=1.743, 95% CI= 1.177–
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2.582, p=0.006; Figure 2D). Mulivariate Cox-regression analysis
also showed that TAZ mRNA expression (HR=1.998, 95%
CI= 1.245–3.205, p=0.004; Figure 2D) was an independent
predictor for survival together with stage (p,0.001) and grade
(p=0.03) of the cancers in this colon cancer patient cohort. On the
other hand, YAP mRNA expression did not significantly correlate
with patient survival by Kaplan-Meier analysis (GSE14333:
p=0.519; Figure 2E and GSE17538: p=0.634; Figure 2F) or by
Cox-regression analysis (GSE14333: p=0.673; Figure 2G and
GSE17538: p=0.979; Figure 3H) in either dataset. These results
suggest that TAZ mRNA expression is a novel prognostic marker
for colon cancer patients, but YAP is not.
Both AXL and CTGF, downstream target genes of TAZ
and YAP, are predictors of patient survival
To investigate whether the functional outcome of the transcrip-
tional program mediated by TAZ and YAP confers prognostic
value in colon cancer patients, we analyzed whether the mRNA
expression of AXL and CTGF, two of the most well defined target
genes of TAZ/YAP-TEAD complexes, correlate with survival of
patients in the two colon cancer patient cohorts.
High level mRNA expression of AXL correlated with a shorter
colon cancer patient survival time in the GSE14333 cohort,
although this correlation was not significant (high level: mean
survival = 80 months, 95% CI= 71–88 months; low level: mean
survival = 114 months, 95% CI= 101–129 months, p=0.064;
Figure 3A). In the GSE17538 cohort, high level mRNA expression
of AXL was significantly correlated with shorter survival (high
level: mean survival = 84 months, 95% CI= 72–96 months; low
level: mean survival = 104 months, 95% CI= 94–114 months,
p=0.004; Figure 3B). By Cox-regression analysis, AXL mRNA
expression was a predictor of patient survival in both the
GSE14333 (HR=1.839, 95% CI= 1.230–2.748, p=0.003;
Figure 3C) and the GSE17538 (HR=2.158, 95% CI= 1.141–
4.081, p=0.018; Figure 3D) cohorts. In the GSE14333 cohort,
AXL mRNA expression (HR=1.631, 95% CI=1.076–2.471,
p=0.021; Figure 3C) was an independent predictor of patient
survival with tumor staging (p,0.001), while in the GSE17538
cohort, AXL mRNA expression (HR=3.700, 95% CI= 1.665–
8.220, p=0.001; Figure 3D) was an independent predictor of
patient survival together with stage (p,0.001) and grade
(p=0.055) of the cancers.
Similar results were obtained for CTGF. A high level of CTGF
mRNA expression was significantly correlated with shorter patient
survival in both GSE14333 (high level: mean survival = 87
months, 95% CI= 74–102 months; low level: mean survival = 98
months, 95% CI= 88–108 months, p=0.012; Figure 3E) and
GSE17538 (high level: mean survival = 85 months, 95% CI=73–
Figure 1. The correlations among mRNA expression of TAZ (WWTR1), YAP (YAP1), AXL and CTGF in colon cancer specimens. Scatter
plots for (A) TAZ mRNA expression versus AXL mRNA expression, (B) TAZ mRNA expression versus CTGF mRNA expression, (C) YAP mRNA expression
versus AXLmRNA expression, and (D) YAP mRNA expression versus CTGFmRNA expression in the GSE14333 colon cancer datasets, and (E) TAZ mRNA
expression versus AXL mRNA expression, (F) TAZ mRNA expression versus CTGF mRNA expression, (G) YAP mRNA expression versus AXL mRNA
expression, and (H) YAP mRNA expression versus CTGF mRNA expression in the GSE17538 colon cancer datasets.
doi:10.1371/journal.pone.0054211.g001
Figure 2. The associations between TAZ or YAP, and survival in colon cancer patients. Kaplan-Meier analyses for TAZ mRNA expression in
(A) GSE14333 and (B) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for TAZ mRNA expression, age,
tumor stage and tumor grade in (C) GSE14333 and (D) GSE17538 colon cancer patient datasets. Kaplan-Meier analyses for YAP mRNA expression in (E)
GSE14333 and (F) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for TAZ mRNA expression, age, tumor
stage and tumor grade in (G) GSE14333 and (H) GSE17538 colon cancer patient datasets.
doi:10.1371/journal.pone.0054211.g002
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97 months; low level: mean survival = 105 months, 95% CI= 95–
114 months, p=0.004; Figure 3F) cohorts. Univariate Cox-
regression analysis also showed that CTGF mRNA expression was
a predictor for patient survival in both cohorts (GSE14333:
HR=1.667, 95% CI=1.260–2.232, p,0.001; Figure 3G and
GSE17538: HR=1.433, 95% CI= 1.126–1.825, p=0.004;
Figure 3H). Moreover, CTGF mRNA expression is an indepen-
dent predictor for survival in both cohorts (GSE14333:
HR=1.543, 95% CI=1.155–2.061, p,0.001; Figure 3G and
GSE17538: HR=1.902, 95% CI=1.385–2.612, p,0.001;
Figure 3H) together with stage (GSE14333: p,0.001 and
GSE17538: p,0.001) and grade (GSE17538: p=0.053) of the
cancers.
TAZ, AXL and CTGF can be used in combination to
predict colon cancer patient survival
As described above, expression of TAZ, AXL and CTGF all
correlated with colon cancer patient survival. We further
investigated whether their expression could be used in combina-
tion as a prognostic marker for colon cancer patients. In the
GSE14333 cohort, patients whose tumors had low level expression
of the three genes had a mean survival time of 117 months (95%
CI= 110–123 months), while those whose tumors overexpressed
only one of the three genes also had a mean survival of 117 months
(95% CI= 101–132 months). Patients whose tumors had a high
level expression of two of the three genes had a mean survival time
of 65 months (95% CI= 57–74 months), while those whose tumors
had a high level expression of all three genes had a mean survival
time of 72 months (95% CI=60–84 months). The survival time of
the patients between these four subgroups were significantly
different (p=0.001; Figure 4A). In Cox-regression analysis, using
the subgroup containing patients whose tumors had a low
expression of all three genes as a reference group, we found that
patients whose tumors overexpressed one (HR=3.953, 95%
CI= 1.070–14.607, p=0.039), two (HR=6.503, 95%
CI= 1.894–22.330, p=0.003) or all the three genes
(HR=7.656, 95% CI= 2.287–25.628, p=0.001) had an increas-
ing risk for disease progression (Figure 4C).
Similar results were obtained in the GSE17538 patient cohort.
Patients whose tumors expressed the three genes at low level had a
mean survival time of 108 months (95% CI=97–119 months),
those whose tumors had a high level expression of one of the three
genes had a mean survival time of 88 months (95% CI= 72–104
months), those whose tumors overexpressed two of the three genes
had a mean survival time of 99 months (95% CI=78–121
months), while those whose tumors overexpressed all three genes
had a mean survival time of 77 months (95% CI=63–91 months).
Increasing incidence of overexpression of these three genes
resulted in significantly shorter survival in these patients
(Kaplan-Meier analysis, p=0.01; Figure 4B). Cox-regression
analysis using tumors that overexpressed none of the three genes
as reference revealed that patients whose tumors overexpressed
one (HR=1.675, 95% CI= 0.75–3.741, p=0.203), two
(HR=1.770, 95% CI= 0.790= 3.966, p=0.166) and all of the
three genes (HR=2.807, 95% CI=1.482–5.317, p=0.002) had
an increased risk for disease progression (Figure 4D).
Indeed, patients whose tumors expressed TAZ, AXL and CTGF
mRNA at low levels (GSE14333: mean survival = 117 months,
95% CI= 110–123; GSE17538: mean survival = 108 months,
95% CI= 95–121 months) had superior survival compared to
those whose tumors overexpressed all the three genes (GSE14333:
Figure 3. The associations between AXL or CTGF, and survival in colon cancer patients. Kaplan-Meier analyses for AXLmRNA expression in
(A) GSE14333 and (B) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for AXL mRNA expression, age,
tumor stage and tumor grade in (C) GSE14333 and (D) GSE17538 colon cancer patient datasets. Kaplan-Meier analyses for CTGF mRNA expression in
(E) GSE14333 and (F) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for CTGF mRNA expression, age,
tumor stage and tumor grade in (G) GSE14333 and (H) GSE17538 colon cancer patient datasets.
doi:10.1371/journal.pone.0054211.g003
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Figure 4. The associations between TAZ-AXL-CTGF expression and survival in colon cancer patients. Patients were divided into 4
groups according to the number of genes that they overexpressed (expressed at above the Median level) among TAZ, AXL and CTGF. Kaplan-Meier
analyses for TAZ-AXL-CTGF mRNA expression in (A) GSE14333 and (B) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox
regression analyses for TAZ-AXL-CTGF mRNA expression, age, tumor stage and tumor grade in (C) GSE14333 and (D) GSE17538 colon cancer patient
datasets.
doi:10.1371/journal.pone.0054211.g004
TAZ in Colorectal Cancer
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Table 1. Genes that are co-regulated with TAZ-AXL-CTGF expression in GSE14333 colon cancer patient cohort.
GSE14333 Number of TAZ/AXL/CTGF that are overexpressed
Gene and phenotype
associated with aberrant
expression 0 1 2 3
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Relative expression levels
Epithelial-Mesencymal transition
ACTA2 97 84–111 105 95–114 120 109–132 147 130–164
ZEB1 76 62–90 92 83–100 112 102–122 163 141–186
ZEB2 21 19–23 28 25–30 29 27–32 37 34–40
Migration and Invasion
DDR2 95 73–117 108 99–117 126 113–139 189 161–217
FERMT2 105 69–140 120 107–132 153 135–171 246 203–288
AKT3 48 43–52 56 51–60 61 56–65 79 72–85
VCAN 469 386–552 671 578–764 728 636–820 1275 1103–1447
Colon cancer biomarkers
EFEMP2 140 125–156 184 166–202 208 187–229 300 268–331
SULF1 687 558–816 1003 867–1139 1126 984–1267 1764 1579–1949
TAGLN 319 208–430 395 347–443 528 435–621 866 705–1026
Calcium binding/signaling
FBN1 156 125–188 217 184–249 234 209–260 415 352–478
CALD1 84 73–96 98 89–106 106 98–114 156 135–177
MGP 66 39–92 84 60–107 106 81–130 301 216–386
MYL9 358 200–515 419 361–477 613 475–752 1137 904–1371
Angiogenesis
ANTXR1 42 39–45 50 46–53 51 47–54 62 57–66
SERPINF1 412 340–485 595 529–662 681 594–768 1038 882–1194
Cytoskeleton associated protein
DPYSL3 44 35–53 58 51–65 59 53–65 101 86–117
PDLIM3 38 28–47 43 39–47 56 50–62 86 73–100
Membrane trafficking
RAB31 343 283–404 489 427–551 556 480–631 786 696–876
RAB34 88 69–107 126 112–140 158 137–179 226 200–252
Focal adhesion
TGFB1I1 205 162–249 260 230–289 314 273–354 459 397–521
TNS1 43 38–48 50 46–54 61 55–66 78 69–87
Hippo pathway related genes
AMOTL1 18 15–22 19 18–21 23 20–25 30 26–33
FRMD6 130 104–155 175 153–197 217 188–246 351 300–401
VGLL3 47 30–64 56 49–63 71 62–80 107 91–123
Tissue inhibitor of MMPs
TIMP2 279 234–323 443 393–492 486 433–538 698 632–763
TIMP3 264 221–307 352 299–404 417 362–471 563 502–624
Others
CCDC80 53 31–76 65 57–73 82 71–92 155 128–182
COL5A1 362 309–416 516 447–586 559 488–630 872 753–991
GEM 361 267–455 474 418–531 534 484–583 945 800–1090
GLT8D2 123 102–144 167 146–187 184 162–205 274 236–311
MSRB3 86 59–113 104 94–115 129 112–146 196 167–225
NNMT 330 265–396 483 414–552 565 473–658 848 731–965
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mean survival = 96, 95% CI= 84–108, p,0.001; GSE17538:
mean survival = 91 months, 95% CI= 81–101 months,
p=0.037; Figure S1).
Neither the age nor sex of the patients was factor that
determined the number of TAZ, AXL and CTGF that
overexpressed in either colon cancer patient cohort. TAZ-AXL-
CTGF expression was only significantly lower in tumors stage A
compared to tumors of other stages (p=0.022), but were not
significantly different between other stages in GSE14333. In
GSE17538, TAZ-AXL-CTGF expression was not significantly
different between AJCC stages or tumor grades. When the patients
were stratified by their stage, we found that TAZ-AXL-CTGF
expression was still significantly correlated with poor survival in
patients with higher stage tumors. In GSE14333, increasing
number of genes overexpressed among TAZ, AXL and CTGF
was significantly correlated with a shorter survival (HR=1.414,
95% CI= 1.031–1.938, p=0.032) in patients with stage C tumors.
Similar results were obtained in GSE17538, in which, TAZ-AXL-
CTGF expression was associated with poorer survival in patients
with tumors of higher grade and higher stage. TAZ-AXL-CTGF
expression was correlated with poorer survival in both grade B
(HR=1.315, 95% CI= 1.026= 1.685, p=0.031) and grade C
(HR=1.671, 95% CI= 1.001–2.790, p=0.05) tumors, as well as
AJCC stage 3 (HR=1.694, 95% CI= 1.075–2.670, p=0.023) and
stage 4 (HR=1.415, 95% CI= 1.074–1.866, p=0.014) tumors.
Identification of genes that are differentially expressed
between TAZ-AXL-CTGF-high and low patients
We found that 39 genes, including TAZ, AXL and CTGF, were
significantly differentially expressed between TAZ-AXL-CTGF-
high and low patients in both datasets. Some of these 39 genes
have been shown to be induced by overexpressing YAP/TAZ-
TEAD complexes in transfected cells [19,29], including Akt3,
CCDC80, FBN1, FRMD6, MSRB3, MYL9, PTRF, TAGLN,
TNS1, VCAN and ZEB1 (Tables 1 and 2). Also co-regulated with
TAZ-AXL-CTGF were genes involved in EMT, migration and
invasion, colon cancer progression, calcium signaling, angiogen-
esis, cytoskeleton association, membrane trafficking, focal adhe-
sion, Hippo pathway regulation, and MMPs inhibition (Tables 1
and 2), suggesting that these biological processes may play an
important role in TAZ-AXL-CTGF-mediated colon cancer
progression.
Individually, as expected because of their strong association with
the TAZ-AXL-CTGF expressions, all of the genes in the list
(Tables 1 and 2) were significantly correlated with patient survival
(p,0.05; data not shown). More importantly, we found that
although none of the genes on the list were associated with patient
survival in the TAZ-AXL-CTGF-high group of patients (data not
shown), MGP, PDLIM3, TAGLN and ZEB2 were predictors of
survival in the TAZ-AXL-CTGF-low group of patients, in the
combined colon cancer patient cohort (Figure 5). When the two
colon cancer patient datasets were combined, as expected, TAZ-
AXL-CTGF mRNA expression levels were associated with patient
survival (p,0.001; Figure 5A). A high level of MGP (p=0.01;
Figure 5B), PDLIM3 (p=0.037; Figure 5C), TAGLN (p=0.044;
Figure 5D) and ZEB2 (p=0.038; Figure 5E) mRNA expression
were correlated with a shorter survival time in the TAZ-AXL-
CTGF-low group of patients. These results suggest that these four
genes may be used as prognostic markers for patients who express
low levels of TAZ, AXL and CTGF mRNA.
Identification of potential small molecules that could
target the 39 gene signature of TAZ-AXL-CTGF co-
expression
Analysis to determine alterations in gene expression following
small molecule treatment of cancer cells revealed a total of 257
small molecules that were associated with a gene expression
signature significantly correlated with the TAZ-AXL-CTGF gene
expression signature (the 25 genes that are presented in bold in
Tables 1 and 2 together with TAZ, AXL and CTGF). Of the 257
small molecules, 164 had a 100% perturbation stability and 138 of
them are inversely correlated with the TAZ-AXL-CTGF gene
expression signature. The results are listed in the supplementary
information. The top 20 small molecules were further analyzed
through a Pubmed search regarding their effects on treatment of
colon cancer. We found that amiloride and tretinoin have yielded
55 and 123 publications, respectively, when coupled with colon
cancer in the search engine. Several publications have shown their
inhibitory effect on colon cancer growth. Amiloride treatment has
been shown to inhibit the growth of colon cancer cells in vitro [45]
and in vivo [46]. Importantly, it can sensitize doxorubicin resistant
colon cancer cells to treatment with doxorubicin [47], suggesting
that amiloride and doxorubicin can be combined to treat
doxorubicin resistant colon cancer. Tretinoin, also known as all-
trans retinoic acid, has been shown to inhibit proliferation and
anchorage-independent growth of colon cancer cells in vitro [48,49]
and in vivo [50], probably through regulating the differentiation
state of cancer cells [51].
Identification of potential therapeutic targets for patients
overexpressing TAZ-AXL-CTGF
We further investigated which genes could be used to further
predict survival in TAZ-AXL-CTGF-high patients; these genes
may be potential therapeutic targets specific for this group of
Table 1. Cont.
GSE14333 Number of TAZ/AXL/CTGF that are overexpressed
Gene and phenotype
associated with aberrant
expression 0 1 2 3
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Relative expression levels
NXN 170 135–205 260 201–320 274 234–314 360 321–400
PTRF 140 117–163 170 157–182 189 172–205 272 242–303
SFRP2 218 100–337 305 208–402 404 296–511 1142 900–1394
doi:10.1371/journal.pone.0054211.t001
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Table 2. Genes that are co-regulated with TAZ-AXL-CTGF expression in GSE17538 colon cancer patient cohort.
GSE17538 Number of TAZ/AXL/CTGF that are overexpressed
Gene and phenotype
associated with aberrant
expression 0 1 2 3
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Relative expression levels
Epithelial-Mesencymal transition
ACTA2 175 165–184 211 198–224 240 228–252 292 269–315
ZEB1 113 106–121 152 140–165 185 171–200 262 234–290
ZEB2 56 54–59 70 66–75 79 75–84 97 92–101
Migration and Invasion
DDR2 203 190–216 250 232–268 316 293–339 440 392–487
FERMT2 133 121–144 201 179–223 259 232–286 416 357–475
AKT3 80 76–84 94 89–100 109 102–116 127 121–133
VCAN 584 515–652 945 823–1066 1314 1126–1503 2188 1958–2419
Colon cancer biomarkers
EFEMP2 243 230–256 310 282–339 403 364–442 513 476–549
SULF1 726 633–818 1186 1026–1345 1897 1665–2129 2803 2578–3029
TAGLN 670 619–722 855 785–925 1215 1055–1375 1779 1562–1996
Calcium binding/signaling
FBN1 169 152–185 263 231–295 376 334–418 623 544–702
CALD1 162 153–171 201 188–214 234 220–249 303 277–330
MGP 101 91–110 151 132–169 207 179–235 381 308–454
MYL9 448 398–498 643 568–717 1010 830–1190 1678 1340–2016
Angiogenesis
ANTXR1 187 180–194 216 206–226 251 240–261 290 278–302
SERPINF1 656 584–728 1106 815–1396 1315 1150–1480 1937 1708–2165
Cytoskeleton associated proteins
DPYSL3 135 125–146 186 168–204 226 204–248 308 280–336
PDLIM3 68 65–71 84 80–89 99 94–104 139 118–160
Membrane trafficking
RAB31 501 443–559 711 619–804 1021 889–1154 1549 1394–1704
RAB34 227 208–247 313 253–372 347 317–378 497 452–542
Focal adhesion
TGFB1I1 388 358–417 465 412–517 672 599–746 880 796–964
TNS1 157 149–165 185 175–195 221 208–235 256 244–268
Hippo pathway related genes
AMOTL1 106 99–114 133 123–143 147 136–157 167 159–175
FRMD6 202 179–224 309 265–353 429 369–490 756 659–853
VGLL3 45 41–50 67 58–76 91 79–103 153 130–176
Tissue inhibitor of MMPs
TIMP2 706 641–771 988 882–1094 1372 1254–1489 1814 1690–1939
TIMP3 485 431–539 694 620–769 959 838–1080 1389 1269–1508
Others
CCDC80 121 112–131 151 137–165 201 182–221 302 262–343
COL5A1 501 451–552 699 602–795 1066 929–1204 1525 1364–1690
GEM 365 328–401 620 533–708 747 648–846 1177 1049–1305
GLT8D2 177 159–195 246 215–276 351 306–395 523 467–579
MSRB3 175 165–186 222 208–237 284 258–310 403 359–446
NNMT 487 436–539 736 651–822 1074 892–1256 1543 1385–1701
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patients whose colon cancers are more aggressive. Therefore, we
compared gene expression in this group of patients between those
patients who were still living and those who were deceased. The
two cohorts’ top 100 differentially expressed genes (based on
survival status) were compared, revealing that ANO1 and SQLE are
the two genes commonly differentially expressed between those
TAZ-AXL-CTGF-high colon cancer patients who are still alive
and those who are deceased. By Kaplan-Meier analysis, we found
that these two genes themselves were associated with patient
survival in both colon cancer datasets (Figure S2). We then
investigated whether the associations between ANO1 or SQLE and
patient survival were specific to patients who overexpressed TAZ,
AXL and CTGF (i.e. the TAZ-AXL-CTGF-high subgroup). A low
level of ANO1 expression was significantly (GSE14333, p=0.002;
Figure 6D and GSE17538, p=0.007; Figure 6L) associated with
better survival in TAZ-AXL-CTGF-high patients in both colon
cancer datasets (GSE1433: high level, mean survival = 59 months,
95% CI= 44–73 months, vs. low level, mean survival = 100
months, 95% CI= 86–114 months; GSE17538: high level, mean
survival = 66 months, 95% CI=51–82 months, vs. low level, mean
survival = 107 months, 95% CI=87–127 months), but was not
associated with survival in patients with other patterns of
expression for TAZ-AXL-CTGF (Figure 6A, B, C, I, J, K).
Similarly, a low level of SQLE expression was significantly
(GSE14333, p=0.02; Figure 6H and GSE17538, p=0.01;
Figure 6P) associated with better survival for TAZ-AXL-CTGF-
high patients in both colon cancer datasets (GSE1433: high level,
mean survival = 55 months, 95% CI= 40–70 months, vs. low level,
mean survival = 88 months, 95% CI= 73–103 months;
GSE17538: high level, mean survival = 62 months, 95%
CI= 45–79 months, vs. low level, mean survival = 86 months,
95% CI= 71–101 months), but was not or less significant in
patients with other patterns of expression for TAZ-AXL-CTGF
(Figure 6E, F, G, M, N, O). When both ANO1 and SQLE genes
were included in multivariate Cox-regression analysis, we found
that mRNA expression of ANO1, but not SQLE, was an
independent predictor of patient survival together with both
tumor stage and TAZ-AXL-CTGF expression in both colon
cancer patient datasets (Tables 3 and 4). These results suggest that
ANO1 and SQLE mRNA expression may determine the aggres-
siveness of TAZ-AXL-CTGF-high tumors and that ANO1 mRNA
expression could be used in combination with TAZ-AXL-CTGF
and tumor stage for better prognostification. Our results also imply
that blockade of ANO1 or SQLE mRNA expression or inhibition of
these two proteins in this group of patients may prolong survival.
The role of TAZ in colon cancer progression in vitro and
in vivo
To confirm the bioinformatics analysis, we investigated the
effect of TAZ knockdown in two colon cancer cell lines, HCT116
and SW620. TAZ knockdown in these two cell lines abolished the
expression of TAZ and down-regulated AXL expression
(Figure 7A). This result is in line with our finding in human
specimens showing that AXL is a downstream target of TAZ.
Knockdown of TAZ also resulted in a significant reduction in the
number of colonies formed in both clonogenic and non-adherent
soft-agar assays in these two cell lines (Figure 7B and C).
Importantly, these in vitro results were replicated in in vivo
tumorigenesis assay. Both HCT116-shTAZ and SW620-shTAZ
cells formed significantly larger tumors in nude mice compared to
HCT116-shScr and SW620-shScr cells, respectively (Figure 7D
and 7E, respectively). Our results suggest that TAZ expression is
required for a higher cell proliferation, non-adherent growth and
tumorigenesis in colon cancer cells, traits that are associated with
colon cancer progression.
Discussion
In the present study, we have shown that TAZ mRNA
expression is positively correlated with two of its downstream
targets, AXL and CTGF, and that TAZ is significantly associated
with poor survival of colon cancer patients in two independent
colon cancer datasets, comprising 522 patients. Interestingly, the
upregulation of AXL and CTGF, which reflects the increased
transcriptional activity of TAZ-TEAD complexes, can be used in
combination with TAZ mRNA expression, for better prognos-
tification in these two independent colon cancer patient datasets.
Genes that are co-regulated with TAZ-AXL-CTGF overexpres-
sion are involved in several important cellular processes, including
cell migration, angiogenesis and calcium signaling, as well as
others that have already been described as prognostic markers for
colon cancer progression. These genes may be upstream factors or
downstream effectors of TAZ and the dysregulated Hippo
pathway in colon cancers. Importantly, we also identified two
potential therapeutic targets, ANO1 and SQLE, for patients with
upregulated TAZ-AXL-CTGF expression; downregulation of
either of these two genes may greatly improve the survival of
TAZ-AXL-CTGF-high colon cancer patients.
An increase in TAZ mRNA may not necessarily correlate with
an increase of its transcriptional activity, due to the fact that TAZ
could be post-translationally regulated via cytoplasmic sequestra-
tion by 14-3-3 [1]. Possible disparity between TAZ mRNA
expression and its transcriptional activity may impair the lone
Table 2. Cont.
GSE17538 Number of TAZ/AXL/CTGF that are overexpressed
Gene and phenotype
associated with aberrant
expression 0 1 2 3
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Relative expression levels
NXN 283 258–308 410 348–472 499 440–559 681 613–748
PTRF 264 246–282 317 293–341 378 344–411 564 513–615
SFRP2 331 210–451 530 383–677 1036 779–1294 2199 1763–2634
doi:10.1371/journal.pone.0054211.t002
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utilization of TAZ mRNA expression as a prognostic marker.
Previously, we have shown that AXL [43] and CTGF [44] are both
downstream targets of the Hippo pathway. In the present study,
we have analyzed the transcriptional outcome of TAZ-TEAD
complexes in colon cancer using AXL or CTGF alone or in
combination with TAZ and found that patients who co-
overexpressed all three genes had significantly poorer survival
compared to those who had other expression patterns. Our results,
therefore, strongly suggest that TAZ, AXL and CTGF can be used
in combination for prognostification in colon cancer patients.
Several genes that are related to EMT are overexpressed in high
TAZ-AXL-CTGF expressing patients (Tables 1 and 2). These include
ACTA2 [52], ZEB1 [53,54] and ZEB2 [55,56]. Interestingly, ZEB1 has
been shown to be a downstream target of TAZ in retinal pigment
epithelial cells [57], suggesting that ZEB1 may act as a downstream
effector of TAZ to promote cancer metastasis, while ZEB1 and ZEB2
have also been shown to be prognostic markers in colon cancer
[53,56]. Genes that govern migration and invasion were also
differentially expressed (Tables 1 and 2). AKT3, which has been shown
to contribute oncogenic functions similar to other AKT isoforms [58],
was up-regulated in the TAZ-AXL-CTGF-high group of patients.
DDR2 [59,60], FERMT2 [61,62,63] and VCAN [64] also play
significant roles in cell adhesion and migration and are upregulated
in TAZ-AXL-CTGF-high group of patients.
Figure 5. Kaplan-Meier analyses for the mRNA expression of TAZ-AXL-CTGF and its co-regulated genes in the combined colon
cancer dataset. (A) Kaplan-Meier analysis for TAZ-AXL-CTGF mRNA expression in the combined colon cancer datasets. Kaplan-Meier analyses for
mRNA expression of (B) MGP, (C), PDLIM3, (D) TAGLN and (E) ZEB2 in colon cancer patients expressing low levels of TAZ-AXL-CTGF (blue line in (A)) in
the combined colon cancer datasets.
doi:10.1371/journal.pone.0054211.g005
TAZ in Colorectal Cancer
PLOS ONE | www.plosone.org 12 January 2013 | Volume 8 | Issue 1 | e54211
Colon cancer biomarkers were also differentially expressed in
these two groups of patients (Tables 1 and 2), namely EFEMP2, a
serum biomarker for early detection of colon cancer [65] and
SULF1, a protein important in colon cancer diagnosis [66] and
whose serum level is elevated in patients with colon adenomas
[67]. Genes that are implicated in angiogenesis were also identified
(Tables 1 and 2); both VCAN [68,69] and ANTXR1 [70,71,72]
promote angiogenesis for cancer progression. Four genes that are
involved in calcium binding or signaling were co-regulated with
TAZ-AXL-CTGF in the colon cancer specimens, including FBN1
[73], CALD1 [74], MGP [75] and MYL9 [76].
Interestingly, genes that play a role in regulating the Hippo
pathway were also co-regulated with TAZ-AXL-CTGF. The
angiomotin family members act as tumor suppressors by inhibiting
the oncogenic functions of YAP and TAZ [44,77], while FRMD6
also acts as an antagonist of YAP by activating Hippo pathway
kinases [78]. In this study, we found that AMOLT1 and FRMD6
are co-overexpressed in TAZ-AXL-CTGF positive tumors,
suggesting that AMOLT1 and FRMD6 may form a negative
regulatory loop with TAZ activation, which requires further
investigation in vitro in colon cancer cell line models. In addition,
VGLL3, which has been shown to act as a co-activator of TEAD
transcription factors is also upregulated in TAZ-AXL-CTGF-high
tumors [79].
Treatments targeting TAZ-AXL-CTGF-high cancers are
required due to the aggressive nature of this type of colon cancer.
We employed two different analyses to identify potential
therapeutic agents and gene targets for this type of cancer. In
sccMap, we found that amiloride and tretinoin may inhibit the
gene expression signature associated with this aggressive type of
colon cancer; these molecules have been shown in the literature to
provide strong inhibitory effects on colon cancer proliferation in
vitro and in vivo. The other 18 small molecules of the top twenty
identified by sccMap as listed in the supplementary information
have yet to be studied in term of their effect on colon cancer
progression driven by the overexpression of TAZ-AXL-CTGF co-
overexpression.
ANO1, also named DOG1, has been shown to be ubiquitously
expressed in gastrointestinal stromal tumors [80] and its overex-
pression is correlated with development of distant metastases in
Figure 6. The prognostic significance of ANO1 and SQLEmRNA expression in colon cancer patients stratified by their TAZ-AXL-CTGF
mRNA expression. Kaplan-Meier analyses for ANO1 mRNA expression in patients overexpressing (A) none, (B) one, (C) two and (D) three of the
three genes (TAZ, AXL and CTGF) in the GSE14333 colon cancer patient datasets. Kaplan-Meier analyses for SQLE mRNA expression in patients
overexpressing (E) none, (F) one, (G) two and (H) three of the three genes in the GSE14333 colon cancer patient datasets. Kaplan-Meier analyses for
ANO1 mRNA expression in patients overexpressing (I) none, (J) one, (K) two and (L) three of the three genes in the GSE17538 colon cancer patient
datasets. Kaplan-Meier analyses for SQLE mRNA expression in patients overexpressed in the GSE17538 colon cancer patient datasets.
doi:10.1371/journal.pone.0054211.g006
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head and neck squamous cell carcinoma [81]. Recently, ANO1 was
shown to promote tumorigenesis and cancer progression via
activating MAPK [82]. In the same study, the authors demon-
strated that pharmacological inhibition of ANO1 resulted in cancer
cell death, however the role of ANO1 in colon cancer progression
has not been examined. In the present study, we found that a low
Figure 7. In vitro and in vivo assays for colon cancer cells expressing scramble shRNA or TAZ shRNA. (A) Western blot showing that
shTAZ specifically knockdown TAZ, but not YAP, and that AXL was down-regulated in shTAZ cells compared to shScr cells. (B) The clonogenicity and
non-adherent growth of HCT116 cells expressing shScr or shTAZ were assessed and the number of colonies formed from three repeats was recorded
(C) The clonogenicity and non-adherent growth of SW620 cells expressing shScr or shTAZ were assessed and the number of colonies formed from
three repeats was recorded. (D) The in vivo tumorigenicity of HCT116 cells expressing shScr or shTAZ was assessed in nude nice, and the tumor
formed was excised and weighted (n = 3 in each group). (E) The in vivo tumorigenicity of SW620 cells expressing shScr or shTAZ was assessed in nude
nice, and the tumor formed was excised and weighted (n = 3 in each group).
doi:10.1371/journal.pone.0054211.g007
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level expression of ANO1 in the aggressive TAZ-AXL-CTGF-high
subgroup of colon cancer patients is associated with prolonged
survival (high level to low level of ANO1 expression; mean survival
from 59 to 100 months and from 66 to 107 month in GSE14333
and GSE17538 patient datasets, respectively), suggesting that
pharmacological inhibition of ANO1 may represent a novel
therapeutic approach for this group of patients with aggressive
colon cancer. ANO1 is a calcium ion-activated chloride channel.
Interestingly, multiple genes involved in calcium signaling (FBN1,
CALD1, MGP and MYL9) were co-overexpressed with TAZ-AXL-
CTGF in colon cancer. Due to the fact that calcium signaling
plays an important role in cancer progression [83,84,85], further
investigation into the relationship between ANO1 and calcium
signaling in TAZ-AXL-CTGF-mediated cancer progression is
warranted. Nonetheless, our results provide a clue to the
involvement of calcium signaling and Ca2+-activated CI2 channels
in colon cancer progression mediated by the Hippo pathway.
Little is known about how SQLE promotes cancer progression.
It has been shown to be overexpressed in lung squamous cell
carcinoma by suppression subtractive hydridization [86], in
pancreatic cancer by genome-wide analysis using microarray
based techniques [87], and in prostate cancer progression by
bioinformatics analysis [88]. Its overexpression in breast cancer is
correlated with decreased distant metastasis-free survival [89].
These results show that SQLE promotes cancer progression in
multiple types of cancer. Again, its role in colon cancer progression
was undefined. In the present study, we also found that a high level
expression of SQLE is associated with poorer survival in TAZ-
AXL-CTGF-high patients to be associated with poorer survival
(high level to low level of SQLE expression; mean survival from 55
to 88 months and from 62 to 102 month in GSE14333 and
GSE17538 patient datasets, respectively), suggesting that SQLE
may be a novel therapeutic target for this group of patients.
In conclusion, this study has shown that TAZ-AXL-CTGF in
combination may be a novel prognostic indicator for colon cancer
progression, and that their overexpression is associated with
increased expression of genes that are associated with colon cancer
progression. Furthermore, ANO1 and SQLE overexpression may
further define a poorer prognosis for colon cancer patients
overexpressing TAZ-AXL-CTGF.
Table 4. Cox-regression analysis of GSE17538 datasets.
Clinicopathological variables Multivariate analysis (Forward conditional)
Hazard ratio (95% CI) p-value
Age (n = 213) 1.024 (1.002–1.046) 0.029
Stage (n = 213) Overall ,0.001
1 (n = 27) 1 Reference
2 (n = 65) 4.089 (0.513–32.586) 0.184
3 (n = 70) 6.898 (0.887–53.641) 0.065
4 (n = 51) 79.966 (10.374–616.406) ,0.001
Hippo pathway activity (n = 213) 0.013
0 gene overexpressed (n = 64) 1 Reference
1 gene overexpressed (n = 38) 1.106 (0.439–2.787) 0.830
2 genes overexpressed (n = 34) 1.050 (0.410–2.691) 0.920
3 genes overexpressed (n = 77) 2.784 (1.208–6.419) 0.016
ANO1 (n = 213) 1.855 (1.286–2.677) 0.001
doi:10.1371/journal.pone.0054211.t004
Table 3. Cox-regression analysis of GSE14333 datasets.
Clinicopathological variables Multivariate analysis (Forward conditional)
Hazard ratio (95% CI) p-value
Stage (n = 226) Overall 0.001
A (n = 41) 1 Reference
B (n = 94) 2.648 (0.592–11.843) 0.203
C (n = 91) 7.213 (1.688–30.817) 0.008
Hippo pathway activity (n = 226) 0.086
0 gene overexpressed (n = 59) 1 Reference
1 gene overexpressed (n = 52) 3.798 (1.009–14.302) 0.049
2 genes overexpressed (n = 54) 4.961 (1.428–17.236) 0.012
3 genes overexpressed (n = 61) 4.505 (1.310–15.492) 0.017
ANO1 (n = 226) 1.550 (1.161–2.069) 0.003
doi:10.1371/journal.pone.0054211.t003
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Supporting Information
Figure S1 Colon cancer patients expressing low levels of
TAZ, AXL and CTGF had superior survival. Patients were
stratified into two groups; those whose tumors expressed TAZ,
AXL and CTGF mRNA at low level (solid line) and those whose
tumors expressed at least one of TAZ, AXL and CTGF at high
level (dotted line). Kaplan-Meier analyses for these two subgroups
of patients in (A) GSE14333 and (B) GSE17538 colon cancer
datasets.
(TIF)
Figure S2 The associations between ANO1 or SQLE,
and survival in colon cancer patients. Kaplan-Meier
analyses for (A) ANO1 and (B) SQLE mRNA expression in the
GSE14333 colon cancer patient dataset. Kaplan-Meier analyses
for (C) ANO1 and (D) SQLE mRNA expression in the GSE17538
colon cancer patient dataset.
(TIF)
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